These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

111 related articles for article (PubMed ID: 1657611)

  • 1. Pharmacokinetics and biochemical efficacy after single and multiple oral administration of N-(2-methyl-2-propyl)-3-oxo-4-aza-5 alpha-androst-1-ene-17 beta-carboxamide, a new type of specific competitive inhibitor of testosterone 5 alpha-reductase, in volunteers.
    Ohtawa M; Morikawa H; Shimazaki J
    Eur J Drug Metab Pharmacokinet; 1991; 16(1):15-21. PubMed ID: 1657611
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Hormonal effects, tolerability, and preliminary kinetics in men of MK-906, a 5 alpha-reductase inhibitor.
    De Schepper PJ; Imperato-McGinley J; Van Hecken A; De Lepeleire I; Buntinx A; Carlin J; Gressi MH; Stoner E
    Steroids; 1991 Sep; 56(9):469-71. PubMed ID: 1666698
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Hormonal effects of an orally active 4-azasteroid inhibitor of 5 alpha-reductase in humans.
    Vermeulen A; Giagulli VA; De Schepper P; Buntinx A; Stoner E
    Prostate; 1989; 14(1):45-53. PubMed ID: 2538808
    [TBL] [Abstract][Full Text] [Related]  

  • 4. MK-386, an inhibitor of 5alpha-reductase type 1, reduces dihydrotestosterone concentrations in serum and sebum without affecting dihydrotestosterone concentrations in semen.
    Schwartz JI; Tanaka WK; Wang DZ; Ebel DL; Geissler LA; Dallob A; Hafkin B; Gertz BJ
    J Clin Endocrinol Metab; 1997 May; 82(5):1373-7. PubMed ID: 9141518
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Effects of finasteride (MK-906), a 5 alpha-reductase inhibitor, on circulating androgens in male volunteers.
    Gormley GJ; Stoner E; Rittmaster RS; Gregg H; Thompson DL; Lasseter KC; Vlasses PH; Stein EA
    J Clin Endocrinol Metab; 1990 Apr; 70(4):1136-41. PubMed ID: 2156887
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Hair growth effects of oral administration of finasteride, a steroid 5 alpha-reductase inhibitor, alone and in combination with topical minoxidil in the balding stumptail macaque.
    Diani AR; Mulholland MJ; Shull KL; Kubicek MF; Johnson GA; Schostarez HJ; Brunden MN; Buhl AE
    J Clin Endocrinol Metab; 1992 Feb; 74(2):345-50. PubMed ID: 1309834
    [TBL] [Abstract][Full Text] [Related]  

  • 7. High-performance liquid chromatographic determination of N-(2-methyl-2-propyl)-3-oxo-4-aza-5 alpha-androst-1-ene-17 beta-carboxamide, a 4-azasteroid, in human plasma from a phase I study.
    Carlin JR; Christofalo P; Vandenheuvel WJ
    J Chromatogr; 1988 May; 427(1):79-91. PubMed ID: 2842353
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Disposition and pharmacokinetics of [14C]finasteride after oral administration in humans.
    Carlin JR; Höglund P; Eriksson LO; Christofalo P; Gregoire SL; Taylor AM; Andersson KE
    Drug Metab Dispos; 1992; 20(2):148-55. PubMed ID: 1352203
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The effect of a 5 alpha-reductase inhibitor on androgen physiology in the immature male rat.
    George FW; Johnson L; Wilson JD
    Endocrinology; 1989 Nov; 125(5):2434-8. PubMed ID: 2551651
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Effect of MK-386, a novel inhibitor of type 1 5 alpha-reductase, alone and in combination with finasteride, on serum dihydrotestosterone concentrations in men.
    Schwartz JI; Van Hecken A; De Schepper PJ; De Lepeleire I; Lasseter KC; Shamblen EC; Winchell GA; Constanzer ML; Chavez CM; Wang DZ; Ebel DL; Justice SJ; Gertz BJ
    J Clin Endocrinol Metab; 1996 Aug; 81(8):2942-7. PubMed ID: 8768856
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Effect of finasteride, a 5 alpha-reductase inhibitor on prostate tissue androgens and prostate-specific antigen.
    Geller J
    J Clin Endocrinol Metab; 1990 Dec; 71(6):1552-5. PubMed ID: 1699965
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Pharmacokinetics and pharmacodynamics of TF-505, a novel nonsteroidal 5alpha-reductase inhibitor, in normal subjects treated with single or multiple doses.
    Fujita T; Matsumoto Y; Kimura T; Yokota S; Sawada M; Majima M; Ohtani Y; Kumagai Y
    Br J Clin Pharmacol; 2002 Sep; 54(3):283-94. PubMed ID: 12236849
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Comparison of finasteride (Proscar), a 5 alpha reductase inhibitor, and various commercial plant extracts in in vitro and in vivo 5 alpha reductase inhibition.
    Rhodes L; Primka RL; Berman C; Vergult G; Gabriel M; Pierre-Malice M; Gibelin B
    Prostate; 1993; 22(1):43-51. PubMed ID: 8381228
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Finasteride, an inhibitor of 5 alpha-reductase, suppresses prostatic dihydrotestosterone in men with benign prostatic hyperplasia.
    McConnell JD; Wilson JD; George FW; Geller J; Pappas F; Stoner E
    J Clin Endocrinol Metab; 1992 Mar; 74(3):505-8. PubMed ID: 1371291
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The androgen control of sebum production. Studies of subjects with dihydrotestosterone deficiency and complete androgen insensitivity.
    Imperato-McGinley J; Gautier T; Cai LQ; Yee B; Epstein J; Pochi P
    J Clin Endocrinol Metab; 1993 Feb; 76(2):524-8. PubMed ID: 8381804
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Effect of MK-906, a specific 5 alpha-reductase inhibitor, on serum androgens and androgen conjugates in normal men.
    Rittmaster RS; Stoner E; Thompson DL; Nance D; Lasseter KC
    J Androl; 1989; 10(4):259-62. PubMed ID: 2550402
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Finasteride for benign prostatic hyperplasia.
    Hasinski S; Miller JL; Rose LI
    Am Fam Physician; 1992 Nov; 46(5):1511-4. PubMed ID: 1279965
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Finasteride: a 5 alpha-reductase inhibitor.
    Steiner JF
    Clin Pharm; 1993 Jan; 12(1):15-23. PubMed ID: 7679063
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Oral testosterone in oil: pharmacokinetic effects of 5alpha reduction by finasteride or dutasteride and food intake in men.
    Amory JK; Page ST; Bremner WJ
    J Androl; 2006; 27(1):72-8. PubMed ID: 16400081
    [TBL] [Abstract][Full Text] [Related]  

  • 20. C19 and C21 5 beta/5 alpha metabolite ratios in subjects treated with the 5 alpha-reductase inhibitor finasteride: comparison of male pseudohermaphrodites with inherited 5 alpha-reductase deficiency.
    Imperato-McGinley J; Shackleton C; Orlic S; Stoner E
    J Clin Endocrinol Metab; 1990 Mar; 70(3):777-82. PubMed ID: 1689740
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.